Board of Directors

Clay Siegall, Ph.D.

Director, Chairman

Clay Siegall, Ph.D.
Director, Chairman

Dr. Siegall previously served as the CEO and President of Seagen, Inc., which he co-founded in July 1997. Under his nearly 25 years of leadership, Seagen became the world leader in ADC therapeutics, earned FDA approvals for four cancer therapies, and grew to over $2 billion in annual revenue. During his tenure, he raised well over $1 billion of financing for Seagen from public and private markets and oversaw the company’s acquisition of Cascadian Therapeutics. Pfizer, Inc. agreed to purchase Seagen for $43 billion in March 2023. Prior to Seagen, Dr. Siegall worked in positions of increasing responsibilities at Bristol Myers Squibb and previously at the National Cancer Institute. He earned a PhD in Genetics at George Washington University and a B.S. in Zoology at the University of Maryland.

Isaac Barchas, J.D.

Lead Independent Director

Isaac Barchas, J.D.
Lead Independent Director and Director

Isaac Barchas is CEO and co-founder of Research Bridge Partners, a biotechnology accelerator. Barchas built RBP’s team and strategy and co-manages new venture creation and investment activity. At Research Bridge Partners, Barchas has served as founding board member of Tetricus, Eradivir, and MorphImmune and as lead turnaround board member of Novosteo (NASDAQ: QNCX). Barchas is also a managing director of RBP-Catalyst Fund I and Arsenal Bridge Ventures II.

Prior to founding Research Bridge Partners, Barchas led the Austin Technology Incubator. Under Barchas’ leadership, ATI companies raised ~$1B in investor capital. Barchas came to ATI from McKinsey & Co., where he served in the Chicago, Sydney, Auckland, and Dallas offices. Barchas served on the leadership teams of McKinsey’s North American Payor/Provider and global Organization practices. Barchas received his AB from Stanford University and his Master’s and JD degrees from The University of Chicago.

Jean-Jacques Bienaimé

Director

Jean-Jacques Bienaimén
Director

Jean-Jacques Bienaimé was appointed to our Board in November 2023. Mr. Bienaimé has served the CEO and a member of the board of directors of BioMarin Pharmaceutical Inc.(BioMarin), a biotechnology company focused on genetic discovery, since May 2005, and served as its chairman of the board since June 2015. Mr. Bienaimé served as Chairman, CEO, and President of Genencor, a biotechnology company focused on industrial bioproducts and targeted cancer biotherapeutics, from November 2002 to April 2005. Prior to Genencor, Mr. Bienaimé served as Chairman, CEO and President of Sangstat Medical Corporation, an immunology-focused biotechnology company, from 1998 to late 2002, becoming President in 1998 and CEO in 1999. Mr. Bienaimé also held several senior management positions at Rhône-Poulenc Rorer Pharmaceuticals (now Sanofi-Aventis) from 1992 to 1998, culminating in the position of Senior Vice President of Worldwide Marketing and Business Development. Earlier in his career, Mr. Bienaimé worked at Genentech, Inc. where he was involved in the launch of tissue plasminogen activator (t-PA) for the treatment of heart attacks. In addition to being a member of BioMarin’s board, Mr. Bienaimé also currently serves on the board of Incyte Corporation, a public biotechnology company, and he is a member of the boards of Biotechnology Innovation Organization (BIO) and Pharmaceutical Research and Manufacturers of America (PhRMA), both industry trade associations. Mr. Bienaimé received an M.B.A. from the Wharton School at the University of Pennsylvania and a degree in economics from the École Supérieure de Commerce de Paris.

James Boylan

Director

James Boylan
Director

James Boylan is Chief Executive Officer of Enavate Sciences and is an accomplished health care executive, entrepreneur, and innovator with nearly three decades of experience. Mr. Boylan most recently served as President and Head of Investment Banking of SVB Leerink, where he architected and led the firm’s transformation into an industry-leading health care investment bank that was acquired by SVB Financial in 2019. Across his 12 years at SVB Leerink and prior 12 years as a Managing Director at Merrill Lynch, Mr. Boylan has worked with hundreds of life sciences and biotechnology companies to develop strategy and complete transactions in capital markets and mergers & acquisitions.

Mr. Boylan earned an M.B.A in finance from the Columbia Business School and a B.S. in finance from Lehigh University.

Philip Wagenheim

Director

Philip Wagenheim
Director

Mr. Wagenheim has more than 28 years of experience in the financial industry and is the Managing Partner of Broadband Capital Partners, LLC, a middle-market private equity sponsor focused on growth companies and industry consolidations. Prior to Broadband Capital Partners, he was the vice-chairman of Broadband Capital Management LLC, an investment and merchant bank he co-founded in 2000. Mr. Wagenheim has extensive experience with public and private growth equity investments, including Zynerba Pharmaceuticals (Nasdaq: ZYNE), ExamWorks (Nasdaq: EXAM), Vroom.com (Nasdaq: VRM) and Montrose Environmental Group. In connection with Zynerba’s recapitalization, Mr. Wagenheim was named President and a Director of the company, serving as a director until the company’s initial public offering in August 2015 led by Jefferies and Piper Jaffray. Mr. Wagenheim received his degree in Business Administration from the University of Miami.

Carol A. Schafer

Director

Carol A. Schafer
Director

Ms. Schafer currently serves as the Managing Partner of Hyphen Advisors. Prior to Hyphen Advisors, Ms. Schafer served as Vice Chair of Wells Fargo Securities, where she led the healthcare equity capital markets team and was responsible for originating and executing equity and convertible financings. Prior to joining Wells Fargo Securities, Ms. Schafer served as Vice President of Finance and Business Development of Lexicon Pharmaceuticals. Previously, Ms. Schafer served as Managing Director, Equity Capital Markets of JPMorgan Chase working with companies in healthcare, retail, consumer and chemical industries. Ms. Schafer earned her MBA from New York University, and her BA in mathematics and computer science from Boston College. Ms. Schafer currently serves on the Board of Directors of Insmed, Repare Therapeutics and Kura Oncology, and previously served on the Board of Directors of Five Prime Therapeutics and Idera Pharmaceuticals.